

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Cephapirin / Prednisolone Formulation

Other means of identification : Mastiplan (A011329)

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-
stance/Mixture : Veterinary product

Recommended restrictions
on use : Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD
Drynam Road
K67 P263 Dublin, Ireland

Telephone : +1-908-740-4000

E-mail address of person
responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

+1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Respiratory sensitisation, Category 1 H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breath-

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

ing difficulties if inhaled.

Precautionary statements : **Response:**
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.

Hazardous components which must be listed on the label:

Cefapirin

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Cefapirin	21593-23-7 244-466-5	Resp. Sens. 1A; H334	$\geq 1 - < 10$
prednisolone	50-24-8 200-021-7	Acute Tox. 4; H302 Repr. 2; H361d STOT RE 1; H372 (Bone marrow, Adrenal gland, Liver) Aquatic Chronic 2; H411	$\geq 0.25 - < 1$

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

- vice immediately.
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.
If not breathing, give artificial respiration.
If breathing is difficult, give oxygen.
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

- Risks : Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).
- May cause allergy or asthma symptoms or breathing difficulties if inhaled.

4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Metal oxides
Silicon oxides

5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Prevent spreading over a wide area (e.g. by containment or oil barriers).
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
Clean up remaining materials from spill with suitable absorbent.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

- | | | |
|-------------------------|---|--|
| Technical measures | : | See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section. |
| Local/Total ventilation | : | Use only with adequate ventilation. |
| Advice on safe handling | : | Do not breathe the mist or vapours.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.
Take care to prevent spills, waste and minimize release to the environment. |
| Hygiene measures | : | If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls. |

7.2 Conditions for safe storage, including any incompatibilities

- | | | |
|---|---|---|
| Requirements for storage areas and containers | : | Keep in properly labelled containers. Keep tightly closed.
Store in accordance with the particular national regulations. |
| Advice on common storage | : | Do not store with the following product types:
Strong oxidizing agents
Gases |

7.3 Specific end use(s)

- | | | |
|-----------------|---|-------------------|
| Specific use(s) | : | No data available |
|-----------------|---|-------------------|

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form	Control parameters	Basis
------------	---------	------------------	--------------------	-------

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version 6.2 Revision Date: 14.04.2025 SDS Number: 766827-00021 Date of last issue: 28.09.2024
Date of first issue: 16.06.2016

		of exposure)		
Glyceryl monos-tearate	123-94-4	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL
Cefapirin	21593-23-7	TWA	0.4 mg/m3 (OEB 2)	Internal
Further information: RSEN				
prednisolone	50-24-8	TWA	10 µg/m3 (OEB 3)	Internal
		Wipe limit	100 µg/100 cm ²	Internal

8.2 Exposure controls

Engineering measures

Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

Eye/face protection : Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter should conform to I.S. EN 14387

Filter type : Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : liquid, oily

Colour : No data available

Odour : No data available

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity
Viscosity, kinematic : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Vapour pressure : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics
Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

Evaporation rate : No data available

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Components:

Cefapirin:

Acute oral toxicity : LD50 (Mouse): 26,000 mg/kg

Acute toxicity (other routes of administration) : LD50 (Mouse): > 7,600 mg/kg
Application Route: Intraperitoneal

LD50 (Rat): 7,800 mg/kg
Application Route: Intraperitoneal

prednisolone:

Acute oral toxicity : LD50 (Mouse): 1,680 mg/kg

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

LD50 (Rat): > 3,857 mg/kg

Acute inhalation toxicity : Remarks: No data available

Acute dermal toxicity : Remarks: No data available

Acute toxicity (other routes of administration) : LD50 (Rat): 147 mg/kg
Application Route: Subcutaneous

LD50 (Mouse): 767 mg/kg
Application Route: Intraperitoneal

Skin corrosion/irritation

Not classified based on available information.

Components:

prednisolone:

Remarks : No data available

Serious eye damage/eye irritation

Not classified based on available information.

Components:

prednisolone:

Remarks : No data available

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Cefapirin:

Assessment : Probability or evidence of high respiratory sensitisation rate in humans

prednisolone:

Remarks : No data available

Germ cell mutagenicity

Not classified based on available information.

Components:

Cefapirin:

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

prednisolone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Mouse Lymphoma
Result: negative

Test Type: sister chromatid exchange assay
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo
cytogenetic assay)
Species: Rat
Application Route: Oral
Result: negative

Test Type: sister chromatid exchange assay
Species: Humans
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

prednisolone:

Species	: Rat
Application Route	: Oral
Exposure time	: 18 Months
Result	: negative

Reproductive toxicity

Not classified based on available information.

Components:

Cefapirin:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Intraperitoneal injection
Fertility: LOAEL: > 500 mg/kg body weight
Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat
Application Route: Intraperitoneal injection
Developmental Toxicity: LOAEL: > 200 mg/kg body weight

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

prednisolone:

- | | | |
|------------------------------------|---|--|
| Effects on fertility | : | Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 1 mg/kg body weight
Result: No effects on fertility |
| Effects on foetal development | : | Test Type: Embryo-foetal development
Species: Mouse
Application Route: Oral
Developmental Toxicity: LOAEL: 0.5 mg/kg body weight
Result: Malformations were observed., Cleft palate

Test Type: Embryo-foetal development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 30 mg/kg body weight
Result: decreased blood formation

Species: Rat
Application Route: Subcutaneous
Developmental Toxicity: NOAEL: 25 mg/kg body weight
Result: No effects on foetal development |
| Reproductive toxicity - Assessment | : | Some evidence of adverse effects on development, based on animal experiments. |

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

prednisolone:

- | | | |
|---------------|---|---|
| Target Organs | : | Bone marrow, Adrenal gland, Liver |
| Assessment | : | Causes damage to organs through prolonged or repeated exposure. |

Repeated dose toxicity

Components:

Cefapirin:

- | | | |
|-------------------|---|-----------------|
| Species | : | Rat |
| LOAEL | : | >= 200 mg/kg |
| Application Route | : | Intraperitoneal |
| Target Organs | : | Blood |
| Remarks | : | anemia |
| Species | : | Dog |

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

LOAEL : 20 mg/kg
Application Route : Oral
Exposure time : 4 Months
Target Organs : Gastrointestinal tract

Species : Dog
LOAEL : 100 mg/kg
Application Route : Intramuscular
Exposure time : 10 Months
Target Organs : Blood, Gastrointestinal tract
Remarks : anemia

prednisolone:

Species : Rat
LOAEL : 0.6 mg/kg
Application Route : Oral
Exposure time : 63 Days
Target Organs : Bone marrow

Species : Dog
LOAEL : 2.5 mg/kg
Application Route : Oral
Exposure time : 6 Weeks
Target Organs : Adrenal gland

Species : Rabbit
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 24 Weeks
Target Organs : Liver

Aspiration toxicity

Not classified based on available information.

11.2 Information on other hazards

Endocrine disrupting properties

Not classified based on available information.

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Experience with human exposure

Components:

Cefapirin:

Ingestion : Symptoms: Nausea, Vomiting, Abdominal pain, Diarrhoea,

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

vaginitis, colitis, anorexia, Rash, anaphylaxis

prednisolone:

Ingestion

: Symptoms: sodium retention, Headache, Vertigo, fluid retention, subcutaneous bleeding, striae, skin atrophy, menstrual irregularities

SECTION 12: Ecological information

12.1 Toxicity

Components:

prednisolone:

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 85 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : NOEC (Pseudokirchneriella subcapitata (green algae)): 160 mg/l
Exposure time: 72 h

EC50 (Pseudokirchneriella subcapitata (green algae)): > 160 mg/l
Exposure time: 72 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 0.23 mg/l
Exposure time: 7 d
Species: Ceriodaphnia dubia (water flea)

12.2 Persistence and degradability

No data available

12.3 Bioaccumulative potential

Components:

prednisolone:

Partition coefficient: n-octanol/water : log Pow: 1.46

12.4 Mobility in soil

No data available

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

14.2 UN proper shipping name

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

14.3 Transport hazard class(es)

ADN	: Not regulated as a dangerous good
-----	-------------------------------------

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

14.4 Packing group

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA (Cargo)	:	Not regulated as a dangerous good
IATA (Passenger)	:	Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Conditions of restriction for the following entries should be considered: Number on list 3
--	---	---

Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable
---	---	----------------

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

Regulation (EU) No 2024/590 on substances that deplete the ozone layer	: Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast)	: Not applicable
Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals	: Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	: Not applicable
Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.	: Not applicable

Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information	: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
-------------------	--

Full text of H-Statements

H302	: Harmful if swallowed.
H334	: May cause allergy or asthma symptoms or breathing difficulties if inhaled.
H361d	: Suspected of damaging the unborn child.
H372	: Causes damage to organs through prolonged or repeated exposure.
H411	: Toxic to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox.	: Acute toxicity
Aquatic Chronic	: Long-term (chronic) aquatic hazard
Repr.	: Reproductive toxicity
Resp. Sens.	: Respiratory sensitisation
STOT RE	: Specific target organ toxicity - repeated exposure
IE OEL	: Ireland. List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Classification of the mixture:

Resp. Sens. 1

H334

Classification procedure:

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by
Commission Regulation (EU) 2020/878



Cephapirin / Prednisolone Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
6.2	14.04.2025	766827-00021	Date of first issue: 16.06.2016

IE / EN